Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 18;13(1):60–70. doi: 10.1158/1535-7163.MCT-13-0518

Figure 3.

Figure 3

p110α hotspot mutations promote lapatinib resistance. (a) BT474 parental (Par) cells were infected with wild-type (WT) HA-tagged p110α, indicated mutants, or vector (Vec) followed by western blot. (b) Cells from (a) were treated 4 days as shown, followed by MTT assay. O.D. readings were normalized to each transductant’s DMSO-treated reading (=100%). Error bars, s.e.m. (*p < 0.001 by one-way ANOVA of lapatinib-treated groups.)